These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 20015823)
21. Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Storebø OJ; Simonsen E; Gluud C JAMA; 2016 May; 315(18):2009-10. PubMed ID: 27163989 [TBL] [Abstract][Full Text] [Related]
22. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084 [TBL] [Abstract][Full Text] [Related]
23. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440 [TBL] [Abstract][Full Text] [Related]
24. Forty years of methylphenidate treatment in Attention-Deficit/ Hyperactivity Disorder. Conners CK J Atten Disord; 2002; 6 Suppl 1():S17-30. PubMed ID: 12685516 [TBL] [Abstract][Full Text] [Related]
25. Hemodynamic profile and behavioral characteristics during induction of anesthesia in pediatric patients with attention deficit hyperactivity disorder. Cartabuke RS; Tobias JD; Rice J; Tumin D Paediatr Anaesth; 2017 Apr; 27(4):417-424. PubMed ID: 28181385 [TBL] [Abstract][Full Text] [Related]
26. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198 [TBL] [Abstract][Full Text] [Related]
27. The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder. Serra-Pinheiro MA; Mattos P; Souza I; Pastura G; Gomes F Arq Neuropsiquiatr; 2004 Jun; 62(2B):399-402. PubMed ID: 15273834 [TBL] [Abstract][Full Text] [Related]
28. Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder. Winters DE; Fukui S; Leibenluft E; Hulvershorn LA J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):298-305. PubMed ID: 29708762 [TBL] [Abstract][Full Text] [Related]
29. [A pilot study of methylphenidate and parent training in the treatment of children with attention-deficit hiperactivity disorder]. Montiel Nava C; Peña JA; Espina Mariñes G; Ferrer-Hernandez ME; López-Rubio A; Puertas-Sánchez S; Cardozo-Durán JJ Rev Neurol; 2002 Aug 1-15; 35(3):201-5. PubMed ID: 12235578 [TBL] [Abstract][Full Text] [Related]
30. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder. Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111 [TBL] [Abstract][Full Text] [Related]
32. [Attention deficit hyperactivity disorder: pharmacological options that are not "Ritalin"]. Shmueli D; Gross-Tsur V Harefuah; 2005 Aug; 144(8):572-6, 597. PubMed ID: 16146157 [TBL] [Abstract][Full Text] [Related]
33. Attention deficit and hyperactivity disorder in people with epilepsy: diagnosis and implications to the treatment. Koneski JA; Casella EB Arq Neuropsiquiatr; 2010 Feb; 68(1):107-14. PubMed ID: 20339664 [TBL] [Abstract][Full Text] [Related]
34. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)]. Stasik D; Tucha O; Tucha L; Walitza S; Lange KW Psychiatr Pol; 2009; 43(2):183-92. PubMed ID: 19697788 [TBL] [Abstract][Full Text] [Related]
35. Megadose intranasal methylphenidate (ritalin) abuse in adult attention deficit hyperactivity disorder. Coetzee M; Kaminer Y; Morales A Subst Abus; 2002 Sep; 23(3):165-9. PubMed ID: 12444349 [TBL] [Abstract][Full Text] [Related]
36. Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate. Wang LJ; Chen CK; Huang YS J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):246-53. PubMed ID: 25574708 [TBL] [Abstract][Full Text] [Related]
37. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137 [TBL] [Abstract][Full Text] [Related]
38. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Groenman AP; Schweren LJ; Dietrich A; Hoekstra PJ Expert Opin Drug Saf; 2017 Apr; 16(4):455-464. PubMed ID: 28277842 [TBL] [Abstract][Full Text] [Related]
39. Response to methylphenidate in boys with attention-deficit hyperactivity disorder. Zeiner P; Bryhn G; Bjercke C; Truyen K; Strand G Acta Paediatr; 1999 Mar; 88(3):298-303. PubMed ID: 10229041 [TBL] [Abstract][Full Text] [Related]
40. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment]. Oberpichler-Schwenk H Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]